Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
NCT06397781Phase 4Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Jan 2031
- Primary completion
- Dec 2035
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mupirocin, chlorhexidine + cymenol gel, trimethoprim + sulfamethoxazole in atopic dermatitis (AD), sponsored by Boston Children's Hospital. Planned start Jan 2031; status: not yet recruiting.
02
Drugs
mupirocinchlorhexidine + cymenol geltrimethoprim + sulfamethoxazole
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06397781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397781.